Glancy Prongay & Murray LLP ("GPM"), announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California, captioned Sookdeo v. Hims & Hers ...

Compounded weight loss drugs have been mostly off the market for about a month, but the weight loss drug industry remains as unsettled as ever.

Granted, defense is not a new theme. The Global X Defense Tech ETF SHLD, which has hot plays including Palantir Technologies (PLTR) and Germany's Rheinmetall (XE:RHM), has surged 54% this year. The ...

The breakup between Novo Nordisk and Hims & Hers remains acrimonious. Recent remarks highlight the competition facing Novo ...

Synthetic food dyes are added to 1 in 5 packaged foods and drinks sold by top U.S. food manufacturers, a new study says.

People living with an autoimmune disease are nearly twice as likely to suffer from mood problems like depression, anxiety or ...

In this week’s edition of InnovationRx, we look at health insurers' vows to improve prior authorization, Bell Labs’ IP ...

Hims & Hers Health HIMS. After $NVO Novo Nordisk abruptly terminated their partnership, citing "deceptive marketing," Hims & Hers fired back with confidence… saying they'll cont ...

Despite Novo Nordisk (NVO) recently ending a partnership with Hims & Hers Health (NYSE:HIMS) to distribute its weight-loss ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

Berger Montague investigates Hims and Hers after stock drops 26% following Novo Nordisk's termination of GLP-1 drug partnership.